Mastering CGT process development: overcoming challenges on the path to commercialization [WEBINAR]

For more information, visit: https://www.miltenyibiotec.com/DE-en/... Bringing cell and gene therapy (CGT) products to market is challenging. In this roundtable, experts discuss overcoming hurdles in CGT process development and manufacturing to help biotech companies achieve commercial readiness. The discussion covers understanding the transition from early drug discovery to commercial CMC, maintaining flexibility and robustness, ensuring scalability and consistency, and managing a successful commercial ramp-up.

Miltenyi Biotec is a global provider of products and services that empower biomedical discovery and advance cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. This integrated portfolio enables scientists and clinicians to obtain, analyze, and utilize the cell. Our technologies offer solutions for cellular research, cell therapy, and cell manufacturing. Our more than 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, cancer, hematology, and graft engineering. In our commitment to the scientific community, we also offer comprehensive scientific support, consultation, and expert training. Today, Miltenyi Biotec has more than 4,700 employees in 23 countries – all dedicated to helping researchers and clinicians around the world make a greater impact on science and health.